Early switch strategy in patients with major depressive disorder

Expert Review of Neurotherapeutics

Volumn 12, Issue 10, 2012, Pages 1185-1188

  Pae, Chi Un ^a,b   Wang, Sheng Min ^a   Lee, Seung Yup ^a,c   Lee, Soo Jung ^a  

^a The Catholic University of Korea   (South Korea)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c Army Cadet Military School   (South Korea)

Author keywords

antidepressant; early switching; major depressive disorder; remission; treatment failure

Indexed keywords

DULOXETINE; ESCITALOPRAM;

ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EARLY SWITCH STRATEGY; EUROGOL 5 DIMENSIONS QUESTIONNAIRE; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; MENTAL PATIENT; OUTPATIENT; PSYCHOLOGICAL RATING SCALE; PSYCHOPHARMACOTHERAPY; QUALITY OF LIFE; QUESTIONNAIRE; REMISSION; SHEEHAN DISABILITY SCALE; SUBSTITUTION THERAPY; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 84867760144     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.12.115     Document Type: Article

References (20)

1. Fava M, Rush AJ, Trivedi MH et al. Background and rationale for the sequenced treatment alternatives to relieve depression (STAR.*D) study. Psychiatr. Clin. North Am. 26(2), 457-494, x (2003).
2. Trivedi MH, Rush AJ, Wisniewski SR et al.; STAR.*D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR.*D: Implications for clinical practice. Am. J. Psychiatry 163(1), 28-40 (2006).
3. Rush AJ, Trivedi MH, Wisniewski SR et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR.*D report. Am. J. Psychiatry 163(11), 1905-1917 (2006).
4. Pae CU, Forbes A, Patkar AA. Aripiprazole as adjunctive therapy for patients with major depressive disorder: Overview and implications of clinical trial data. CNS Drugs 25(2), 109-127 (2011).
5. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (revision). Am. J. Psychiatry 157(4 Suppl.), 1-45 (2000).
6. Nierenberg AA, Farabaugh AH, Alpert JE et al. Timing of onset of antidepressant response with fluoxetine treatment. Am. J. Psychiatry 157(9), 1423-1428 (2000).
7. Szegedi A, Müller MJ, Anghelescu I, Klawe C, Kohnen R, Benkert O. Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression. J. Clin. Psychiatry 64(4), 413-420 (2003).
8. Posternak MA, Zimmerman M. Is there a delay in the antidepressant effect? A meta-analysis. J. Clin. Psychiatry 66(2), 148-158 (2005).
9. Taylor MJ, Freemantle N, Geddes JR, Bhagwagar Z. Early onset of selective serotonin reuptake inhibitor antidepressant action: Systematic review and metaanalysis. Arch. Gen. Psychiatry 63(11), 1217-1223 (2006).
10. Papakostas GI, Perlis RH, Scalia MJ, Petersen TJ, Fava M. A meta-analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder. J. Clin. Psychopharmacol. 26(1), 56-60 (2006).
11. van Calker D, Zobel I, Dykierek P et al. Time course of response to antidepressants: Predictive value of early improvement and effect of additional psychotherapy. J. Affect. Disord. 114(1-3), 243-253 (2009).
12. Henkel V, Seemüller F, Obermeier M et al. Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression. J. Affect. Disord. 115(3), 439-449 (2009).
13. Lin CH, Lane HY, Chen CC, Juo SH, Yen CF. Early prediction of fluoxetine response for Han Chinese inpatients with major depressive disorder. J. Clin. Psychopharmacol. 31(2), 187-193 (2011).
14. Tadic A, Helmreich I, Mergl R et al. Early improvement is a predictor of treatment outcome in patients with mild major, minor or subsyndromal depression. J. Affect. Disord. 120(1-3), 86-93 (2010).
15. Romera I, Pérez V, Menchón JM et al. Early Switch Strategy in Patients With Major Depressive Disorder: A Double- Blind, Randomized Study. J. Clin. Psychopharmacol. 32(4), 479-486 (2012).
16. Rush AJ, Warden D, Wisniewski SR et al. STAR.*D: Revising conventional wisdom. CNS Drugs 23(8), 627-647 (2009).
17. Nierenberg AA, McLean NE, Alpert JE, Worthington JJ, Rosenbaum JF, Fava M. Early nonresponse to fluoxetine as a predictor of poor 8-week outcome. Am. J. Psychiatry 152(10), 1500-1503 (1995).
18. Papakostas GI, Petersen T, Sklarsky KG, Nierenberg AA, Alpert JE, Fava M. Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder. Psychiatry Res. 149(1-3), 195-200 (2007).
19. Tedeschini E, Fava M, Papakostas GI. Placebo-controlled, antidepressant clinical trials cannot be shortened to less than 4 weeks' duration: A pooled analysis of randomized clinical trials employing a diagnostic odds ratio-based approach. J. Clin. Psychiatry 72(1), 98-118 (2011).
20. Nierenberg AA, Quitkin FM, Kremer C, Keller MB, Thase ME. Placebo-controlled continuation treatment with mirtazapine: Acute pattern of response predicts relapse. Neuropsychopharmacology 29(5), 1012-1018 (2004).